top of page

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

  • blonca9
  • 22 minutes ago
  • 1 min read

Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

​

​Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page